AGC Biologics Inc. has completed an approximately 30,000-square-foot-expansion to its Longmont facility on Nelson Road. The pharmaceutical plant now has the ability to work on cell and gene therapy manufacturing.
“Now, AGC Biologics Longmont can offer end-to-end cell therapy development and manufacturing services in one location,” AGC said in a news release Wednesday. “The new labs extend the capabilities at the site and complement the site’s robust viral vector development and manufacturing services, offering unique benefits to developers looking for one centralized location that can offer a full set of services for bringing their products to market.”
The expansion has added three cell-therapy production suites to the plant. According to AGC, the Nelson Road campus has the space build nine more production suites in the future.
“The new cell therapy suites are a tremendous achievement for this site. We have integrated the latest technology to complete our unique cell therapy services and have created ideal environments for developing these life-changing treatments,” AGC Colorado general manager Whitney Sandberg said in a statement. “This is the final piece for this campus that accompanies our comprehensive viral vector capabilities and gives developers a true end-to-end manufacturing site in North America to support their product’s every need, at any stage.”
According to reporting from BizWest, this expansion project cost an estimated $30 million. The groundbreaking took place in May.
AGC is currently planning on furthering their expansion in Colorado, with a site in Boulder, located at 5550 Airport Blvd. AGC purchased the facility from Astrazeneca in 2019.
